ZA200207111B - Use of deramciclane for the treatment of anxiety and depression. - Google Patents
Use of deramciclane for the treatment of anxiety and depression. Download PDFInfo
- Publication number
- ZA200207111B ZA200207111B ZA200207111A ZA200207111A ZA200207111B ZA 200207111 B ZA200207111 B ZA 200207111B ZA 200207111 A ZA200207111 A ZA 200207111A ZA 200207111 A ZA200207111 A ZA 200207111A ZA 200207111 B ZA200207111 B ZA 200207111B
- Authority
- ZA
- South Africa
- Prior art keywords
- deramciclane
- substance
- composition
- treatment
- daily dosage
- Prior art date
Links
- 229950011405 deramciclane Drugs 0.000 title claims description 64
- QOBGWWQAMAPULA-RLLQIKCJSA-N n,n-dimethyl-2-[[(1r,3s,4r)-4,7,7-trimethyl-3-phenyl-3-bicyclo[2.2.1]heptanyl]oxy]ethanamine Chemical compound C1([C@@]2([C@]3(C)CC[C@@H](C3(C)C)C2)OCCN(C)C)=CC=CC=C1 QOBGWWQAMAPULA-RLLQIKCJSA-N 0.000 title claims description 64
- 238000011282 treatment Methods 0.000 title claims description 49
- 208000019901 Anxiety disease Diseases 0.000 title claims description 30
- 230000036506 anxiety Effects 0.000 title claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 19
- 241000282412 Homo Species 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 9
- 230000000862 serotonergic effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000012735 once-a-day formulation Substances 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 21
- 238000004519 manufacturing process Methods 0.000 claims 7
- 241000700159 Rattus Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 12
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 206010054089 Depressive symptom Diseases 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005333 tetrabenazine Drugs 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00302207A EP1133986A1 (en) | 2000-03-17 | 2000-03-17 | Use of deramciclane for the treatment of anxiety and depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200207111B true ZA200207111B (en) | 2003-12-04 |
Family
ID=8172804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200207111A ZA200207111B (en) | 2000-03-17 | 2002-09-04 | Use of deramciclane for the treatment of anxiety and depression. |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1133986A1 (cs) |
| JP (1) | JP2004500394A (cs) |
| KR (1) | KR20020089399A (cs) |
| CN (1) | CN1418094A (cs) |
| AR (1) | AR028260A1 (cs) |
| AU (2) | AU4838301A (cs) |
| BG (1) | BG107196A (cs) |
| BR (1) | BR0109172A (cs) |
| CA (1) | CA2403350A1 (cs) |
| CZ (1) | CZ20023025A3 (cs) |
| EA (1) | EA200200987A1 (cs) |
| HU (1) | HUP0204528A3 (cs) |
| IL (1) | IL151493A0 (cs) |
| MX (1) | MXPA02008998A (cs) |
| NO (1) | NO20024331L (cs) |
| PL (1) | PL359288A1 (cs) |
| SK (1) | SK12982002A3 (cs) |
| WO (1) | WO2001068067A2 (cs) |
| ZA (1) | ZA200207111B (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20002612A0 (fi) * | 2000-11-28 | 2000-11-28 | Orion Yhtymae Oyj | Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi |
| CN105456257A (zh) * | 2014-09-25 | 2016-04-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 胺类化合物的光学异构体治疗焦虑障碍的医药用途 |
| CN109758452A (zh) * | 2014-09-25 | 2019-05-17 | 石药集团中奇制药技术（石家庄）有限公司 | 胺类化合物治疗疼痛的医药用途 |
| CN105497021A (zh) * | 2014-09-25 | 2016-04-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 胺类化合物治疗焦虑障碍的医药用途 |
| CN105497020A (zh) * | 2014-09-25 | 2016-04-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 胺类化合物的光学异构体治疗疼痛的医药用途 |
-
2000
- 2000-03-17 EP EP00302207A patent/EP1133986A1/en not_active Withdrawn
-
2001
- 2001-03-16 CZ CZ20023025A patent/CZ20023025A3/cs unknown
- 2001-03-16 CA CA002403350A patent/CA2403350A1/en not_active Abandoned
- 2001-03-16 PL PL01359288A patent/PL359288A1/xx unknown
- 2001-03-16 EP EP01921387A patent/EP1263424A2/en not_active Withdrawn
- 2001-03-16 MX MXPA02008998A patent/MXPA02008998A/es unknown
- 2001-03-16 WO PCT/FI2001/000266 patent/WO2001068067A2/en not_active Application Discontinuation
- 2001-03-16 BR BR0109172-7A patent/BR0109172A/pt not_active Application Discontinuation
- 2001-03-16 AU AU4838301A patent/AU4838301A/xx active Pending
- 2001-03-16 AU AU2001248383A patent/AU2001248383A1/en not_active Abandoned
- 2001-03-16 CN CN01806697A patent/CN1418094A/zh active Pending
- 2001-03-16 SK SK1298-2002A patent/SK12982002A3/sk unknown
- 2001-03-16 JP JP2001566631A patent/JP2004500394A/ja active Pending
- 2001-03-16 AR ARP010101239A patent/AR028260A1/es unknown
- 2001-03-16 HU HU0204528A patent/HUP0204528A3/hu unknown
- 2001-03-16 EA EA200200987A patent/EA200200987A1/ru unknown
- 2001-03-16 KR KR1020027012243A patent/KR20020089399A/ko not_active Withdrawn
- 2001-03-16 IL IL15149301A patent/IL151493A0/xx unknown
-
2002
- 2002-09-04 ZA ZA200207111A patent/ZA200207111B/en unknown
- 2002-09-10 NO NO20024331A patent/NO20024331L/no not_active Application Discontinuation
- 2002-10-15 BG BG107196A patent/BG107196A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001248383A1 (en) | 2002-07-16 |
| AR028260A1 (es) | 2003-04-30 |
| PL359288A1 (en) | 2004-08-23 |
| AU4838301A (en) | 2001-09-24 |
| WO2001068067A2 (en) | 2001-09-20 |
| JP2004500394A (ja) | 2004-01-08 |
| CZ20023025A3 (cs) | 2003-05-14 |
| EA200200987A1 (ru) | 2003-04-24 |
| HUP0204528A2 (en) | 2003-05-28 |
| HUP0204528A3 (en) | 2004-08-30 |
| NO20024331D0 (no) | 2002-09-10 |
| EP1263424A2 (en) | 2002-12-11 |
| KR20020089399A (ko) | 2002-11-29 |
| MXPA02008998A (es) | 2003-04-25 |
| IL151493A0 (en) | 2003-04-10 |
| NO20024331L (no) | 2002-09-10 |
| EP1133986A1 (en) | 2001-09-19 |
| CA2403350A1 (en) | 2001-09-20 |
| BR0109172A (pt) | 2002-11-26 |
| WO2001068067A3 (en) | 2002-07-11 |
| CN1418094A (zh) | 2003-05-14 |
| BG107196A (bg) | 2003-02-28 |
| SK12982002A3 (sk) | 2003-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Finder et al. | Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness | |
| Nemeroff | Improving antidepressant adherence | |
| US20080004338A1 (en) | Use of enantiomeric pure escitalopram | |
| DE60009697T2 (de) | Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie | |
| KR20060109493A (ko) | 비만을 치료하기 위한 조합 약물 치료 | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| PH12015501302B1 (en) | Compositions comprising vortioxetine and donepezil | |
| JP2005537307A (ja) | のぼせの治療のためのレボキセチンの使用 | |
| ZA200207111B (en) | Use of deramciclane for the treatment of anxiety and depression. | |
| US6589996B2 (en) | Treatment of disorders relating to the serotonergic system | |
| NZ236055A (en) | Use of pyrimidine-substituted piperazine derivative in the treatment of depression | |
| Kasper et al. | Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder | |
| JP2012500248A (ja) | 不安障害の治療 | |
| EP1727531A1 (en) | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions | |
| EP1345599A1 (en) | Treatment of obsessive compulsive disorder | |
| HK1051972A (en) | Treatment of disorders relating to the serotonergic system | |
| SK2222004A3 (en) | Citalopram for the treatment of elevated blood pressure | |
| Langdon | Sertraline and dothiepin in the treatment of depression in general practice—a placebo controlled study | |
| CA2338330A1 (en) | Use of moclobemide for treating certain phsychiatric and medical disorders | |
| WO2002043727A1 (en) | Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives | |
| WO2004037238A1 (en) | New uses of deramciclane | |
| Deahl | Pharmacological treatment of depression: The role of paroxetine | |
| Malitas et al. | Lithium treatment response in bipolar affective disorder coexisting with multiple sclerosis: A case report | |
| Lecrubier | P. 1.152 Use of the mini-international neuropsychiatric interview to diagnose comorbid depression and anxiety | |
| Kumar | P. 1.151 Efficacy and tolerability of paroxetine in the long-term management of panic |